Movement Alert|MetLife Rises 3.16% in Regular Trading, Q2 Variable Investment Income Guidance Signals Strong Progress Toward Full-Year Target

Market Focus
Jul 02

On July 2, MetLife rose 3.16% in regular trading, trading at $87.27/share, with turnover of $89.89 million.

On the news front, MetLife filed with the SEC on June 29 disclosing that Q2 pre-tax variable investment income is expected to range between $220 million and $270 million, while maintaining its full-year guidance of $1.6 billion. Combined with Q1 actual variable investment income of $518 million — which represented a 58% year-over-year increase driven by improved private equity returns — the first-half total is projected at approximately $738 million to $788 million, representing 46% to 49% of the annual target. This pace indicates solid execution toward the full-year objective.

The company is scheduled to release its complete Q2 earnings on August 5, with consensus EPS estimates at $2.44. Analyst sentiment remains broadly constructive, with the average rating at overweight and a mean price target of approximately $93.73. Recent target price adjustments include Piper Sandler raising to $90 and Argus raising to $93, both maintaining positive ratings.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10